[1]It G R, Singh S B, Hamel E, et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastain A-4[J]. Experientia,1989, 45(2): 209-211.
[2]Gaukroger K, Hadfield J A, Lawrence N J, et al. Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit?[J]. Org Biomol Chem, 2003, 1(17): 3033-3037.
[3]Pettit G R, Minardi M D, Rosenberg H J, et al. Antineo plastic agents509:synthesis of fluorcombstat in phosphateandrelated 3-halostilbenes[J]. J Nat Prod, 2005, 68(10): 1450-1458.
[4]Pettit G R, Anderson C R, Herald D L, et al .Antineo plastic agents 487.synthesis and biological evaluation of the antineo-plastic agent 3,4-methylene dioxy-5,4′-dimethoxy-3′-amino-Z-stilbene and derived aminoacidamides[J]. J Med Chem, 2003, 46(4): 525-531.
[5]John J H, Madhavi S, Tracy E S, et al. Design, synthesis, biochemical, and biological evaluation of evaluation of nitrogen-containing trifluoro structural modifications of combretastain A-4[J]. Bioorg Med ChemLett, 2008, 18(18): 5146-5149.
[6]Maya A B S, Del Rey B, de Clairac R P L, et al. Design, synthesis and cytotoxic activities of naphthylanphthyl analogues of combretastain A-4[J]. Bioorg Med ChemLett, 2000, 10(22) : 2549-2551.
[7]Hu L, Li Z R,Wang Y M, et al. Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents[J]. Bioorg Med Chem Lett, 2007, 17(5): 1193-1196.
[8]Ohsumi K, Nakagawa R, Fukuda Y, et al. Novel combretastatinananlogues effective against murine solid tumors: Design and structure-activity relationships[J]. J Med Chem, 1998, 41(16): 3022-3032.
[9]Pinney K G, Mejia M P, Villalobos V M, et al. Synthesis and biological evaluation of aryl azide derivatives of combretastatin A-4 as molecular probes for tubulin[J]. Bioorg Med Chem, 2000, 8(10): 2417-2425.
[10]Monk K, Siles R, Hadimani M B, et al. Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents[J]. Bioorg Med Chem, 2006, 14(9): 3231-3244.
[11]Hatanaka T, Fujita K, Ohsumi K, et al. Novel B -ring modified combretastatin analogues: Syntheses and an tineoplasticactivity[J]. Bioorg Med Chem Lett,1998,8(23): 3371-3374.
[12]Rao Y K, Fang S H, Tzeng Y M. Synthesis and biological evaluation of 3′,4′,5′-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell proliferation[J]. Bioorg Med Chem, 2009,17(23) : 7909-7914.
[13]汪忠华. 一种1-取代苯基-4-取代苯胺甲基-1,2,3-三氮唑衍生物及其制备方法和用途:中国,201410834545.2[P].2014-12-23.
[14]巫辅龙. 二苯基取代氨甲基三氮唑类化合物的合成和活性研究[D]. 上海:上海应用技术大学,2016. |